AA
CYT

AlphaCentric Advisors’s Cyteir Therapeutics, Inc. Common Stock CYT Stock Holding History

AlphaCentric Advisors’s Portfolio CYT Stock Details CYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,000
Closed -$21K – 219
2021
Q2 		$21K Buy
+1,000
New +$18.7K 0.01% 208

Other funds holding CYT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
CCM
CAAS Capital Management New York $934M AUM 1.45% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AlphaCentric Advisors's CYT Position: Q3 2021 in Review

AlphaCentric Advisors sold out of Cyteir Therapeutics, Inc. Common Stock (CYT) in Q3 2021, closing a stake of 1,000 shares — an estimated $21K sold.

AlphaCentric Advisors first reported a position in CYT in Q2 2021 and held it in 1 quarter. The position peaked at $21K in Q2 2021. 38 funds tracked by Wall St. Rank hold CYT as of Q3 2021.

  • AlphaCentric Advisors reported no remaining Cyteir Therapeutics, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • AlphaCentric Advisors sold 1,000 Cyteir Therapeutics, Inc. Common Stock shares in Q3 2021, an estimated $21K.
  • AlphaCentric Advisors first reported a position in Cyteir Therapeutics, Inc. Common Stock in Q2 2021 and held it in 1 quarter.
  • AlphaCentric Advisors's Cyteir Therapeutics, Inc. Common Stock position peaked at $21K in Q2 2021.
  • 38 funds tracked by Wall St. Rank held Cyteir Therapeutics, Inc. Common Stock as of Q3 2021.

Based on AlphaCentric Advisors's 13F filing for Q3 2021, filed 9 Mar 2022.